Does SION pay a dividend and is it safe?

Sionna Therapeutics Inc. (SION) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / SION / dividends

TRDA (16) ORMP (33) ANTX (43) ADAG (25) ⌘ Pro Terminal →

Sionna Therapeutics Inc. (SION) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.73 -3.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.70

Sionna Therapeutics Inc. (SION) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $175.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SION Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SION stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Sionna Therapeutics Inc. (NASDAQ: SION) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.73 (-3.62% 1D, market cap $175.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SION ranks #683 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SION compare to TRDA and ORMP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SION carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, TRDA (Entrada Therapeutics Inc.) holds a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $176.6M) and ORMP (Oramed Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -7.8%, cap $171.0M). Among the 5-stock peer group, SION leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SION?

▼

Per SION's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002036042), Sionna Therapeutics Inc. generated $249.1M in revenue (+26.1% YoY), -$75.3M in net income, and -$66.7M in free cash flow against $326.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.70 (-0.84%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SION)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY SION SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.38-5.3% Next Q

Q2 (-2Q)

Grade E$4.15-6.7% Next Q

Q3 (-1Q)

Grade E$3.87-3.6% Next Q

Current

Grade E$3.73-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SION Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SION currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.38) and Max Pain ($3.92) forces dealer call-delta covering toward $57.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SION• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SION Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SION)

✓Walkthrough of SION's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SION // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.78%🛡️ HOLDING TREND SUPPORT

2026-11-03O $4.00H $4.00L $3.73C $3.73VOL 534.4K

RES: $61.50SUP: $3.49SMA50: $5.38SMA200: $29.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SION Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SION Butterfly Map → + Track SION →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +26.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SION today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SION. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SION today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SION)

Health Care Rank #683 of 1015 ⚔️ TRDA vs SION Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SION vs. TRDA, ORMP, ANTX, ADAG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sionna Therapeutics Inc. (SION) ranks #683 by composite RQD confidence (33/100, grade E) and #589 by equity capitalization ($175.0M). Within this direct 5-issuer industry benchmark cohort, SION leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with SION at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SION ACTIVE Sionna Therapeutics Inc.	E	33/100	—	—	-28.3%	-3.62%	$175.0M	Benchmark Subject
TRDA Entrada Therapeutics Inc.	E	16/100	—	—	-35.0%	+12.68%	$176.6M	/trda-vs-sion →
ORMP Oramed Pharmaceuticals Inc.	E	33/100	—	0.7%	-7.8%	-2.68%	$171.0M	/ormp-vs-sion →
ANTX AN2 Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.97%	$170.9M	/antx-vs-sion →
ADAG Adagene Inc.	E	25/100	—	—	-35.0%	-8.76%	$165.8M	/adag-vs-sion →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002036042 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sionna Therapeutics Inc. (SION) reported GAAP revenue of $249.1M (+26.1% vs. FY2024 revenue of $197.6M ) , GAAP net income of -$75.3M, operating cash flow of -$66.3M, and free cash flow of -$66.7M (-26.2% YoY). On the balance sheet, SION closed FY2025 with $326.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$249.1M	-$75.3M	-$66.3M	-$66.7M	$326.0M	—
FY2024 (FY)	2024-12-31	$197.6M	-$61.7M	-$52.8M	-$52.8M	$185.8M	—

3. SION Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SION stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SION compare to TRDA and ORMP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SION?

Where is SION trading relative to its 50-day, 200-day, and 52-week technical levels?

SION last traded at $3.73 (-3.62% on volume of 655,451 shares), positioning the stock -30.67% below its 50-day simple moving average ($5.38) and -87.46% below its 200-day simple moving average ($29.75). Across its 52-week range of $3.55 to $54.97, SION sits at the 0.4% percentile with a 14-day RSI of 33.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.26 to $4.20).

Direct Sub-Reports: SION RQD Cockpit SION 12M Forecast SION Earnings & Move SION Dividends & DRIP SION Insiders & 13F SION Whale Options SION Profit Sankey SION News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

SION — Sionna Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sionna Therapeutics Inc. (SION) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.73 (-3.62% 1D, market capitalization $175.0M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -28.3%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (SION) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The source data states a market capitalization of $0.2B. Product lines, customer base, and revenue model are — Reported revenue for FY 2025 and FY 2024 is — in each period, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sionna Therapeutics Inc. (SION) reported $249.1M in annual revenue (up from $197.6M in FY2024, +26.1% YoY) and -$75.3M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($197.6M revenue, -$61.7M net income) through FY2025, SION scaled operating cash flow to -$66.3M and free cash flow to -$66.7M, backed by $326.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.55 – $54.97 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations beyond the Beta of 1.0 are — Investors should note that the absence of graph data is itself a gap, not evidence of isolation from the sector.

Key Question #1: Can SION sustain or expand its — operating margin and -28.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $249.1M and free cash flow of -$66.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SION's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SION Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sionna Therapeutics Inc. (SION) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SION Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Clinical Trial Vanguard • 1d ago

Sionna Advances SION-451/SION-2222 Combo Based on SION-719 Analysis

The Clinical Trial Vanguard report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com South Africa • 1d ago

Form 4 Sionna Therapeutics Inc: Michael Cloonan (Director, President & CEO) For: 17 September By Investing.com

Investing.com South Africa report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences

Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 2d ago

Sionna Therapeutics, Inc. (SION) Seasonal returns chart

Yahoo Finance Australia report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 2d ago

SION Q2 2026 Earnings: Narrower-Than-Expected Loss Keeps Clinical-Stage Story on Track - Operating Margin Analysis

https://www.dars.gov.et/ report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SION Bull vs. Bear Conversation Board — What's Your Call at $3.73?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SION 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $4.64 (+19.9%)

📌 Pinned Debate

Reported cash rose from $37.8M to $58.5M while the forensic pillar scores Altman Z 2.5, indicating a balance sheet not acutely stressed

Long SION at $3.87 targeting $4.64. Reported cash rose from $37.8M to $58.5M while the forensic pillar scores Altman Z 2.5, indicating a balance sheet not acutely stressed by the data provided.. Institutional whale score is 3/20 and the risk/reward vs. the $3.55 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.02 (-22.0%)

Spot @ $3.87

Zero reported revenue, FY 2025 operating loss of -$89.0M, FCF of -$66.7M, and ROIC of -28.3% leave the Fundamental Cash Engine pillar a

I respect the product at Sionna Therapeutics Inc., but the stock at $3.87 is a different story. Zero reported revenue, FY 2025 operating loss of -$89.0M, FCF of -$66.7M, and ROIC of -28.3% leave the Fundamental Cash Engine pillar at 7/20.. FCF yield is 0.0% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?